{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:22:52Z","timestamp":1791159772519,"version":"4.1.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,6,30]]},"DOI":"10.18632\/oncotarget.2056","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:39:30Z","timestamp":1442360370000},"page":"4504-4515","source":"Crossref","is-referenced-by-count":25,"title":["New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells"],"prefix":"10.18632","volume":"5","author":[{"given":"Fabien","family":"Gueugnon","sequence":"first","affiliation":[{"name":"Inserm, U892, F-44000, Nantes, France"},{"name":"CNRS, UMR6299, F-44000, Nantes, France"},{"name":"Universit\u00e9 Nantes, F-44000, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"Cartron","sequence":"additional","affiliation":[{"name":"Inserm, U892, F-44000, Nantes, France"},{"name":"CNRS, UMR6299, F-44000, Nantes, France"},{"name":"Universit\u00e9 Nantes, F-44000, Nantes, France"},{"name":"R\u00e9seau Epig\u00e9n\u00e9tique du Cancerop\u00f4le Grand Ouest"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Charrier","sequence":"additional","affiliation":[{"name":"CNRS, UMR7285, Institut de Chimie des Milieux et Mat\u00e9riaux de Poitiers, Universit\u00e9 de Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bertrand","sequence":"additional","affiliation":[{"name":"R\u00e9seau Epig\u00e9n\u00e9tique du Cancerop\u00f4le Grand Ouest"},{"name":"CNRS, UMR7285, Institut de Chimie des Milieux et Mat\u00e9riaux de Poitiers, Universit\u00e9 de Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Fonteneau","sequence":"additional","affiliation":[{"name":"Inserm, U892, F-44000, Nantes, France"},{"name":"CNRS, UMR6299, F-44000, Nantes, France"},{"name":"Universit\u00e9 Nantes, F-44000, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gregoire","sequence":"additional","affiliation":[{"name":"Inserm, U892, F-44000, Nantes, France"},{"name":"CNRS, UMR6299, F-44000, Nantes, France"},{"name":"Universit\u00e9 Nantes, F-44000, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[{"name":"Inserm, U892, F-44000, Nantes, France"},{"name":"CNRS, UMR6299, F-44000, Nantes, France"},{"name":"Universit\u00e9 Nantes, F-44000, Nantes, France"},{"name":"R\u00e9seau Epig\u00e9n\u00e9tique du Cancerop\u00f4le Grand Ouest"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,6,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejca.2012.02.047","article-title":"Rare thoracic cancers, including peritoneum mesothelioma","volume":"48","author":"Ardanaz","year":"2012","journal-title":"Eur J Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Scagliotti","year":"2011","journal-title":"J Thorac Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"van Meerbeeck","year":"2010","journal-title":"Eur Respir J"},{"key":"4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1164\/rccm.201001-0045UP","article-title":"Meert: Update in lung cancer and mesothelioma 2009","volume":"181","author":"Berghmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Kelsey","year":"2009","journal-title":"Cancer Res"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Liloglou, Bediaga, Brown, Field, Davies. Epigenetic biomarkers in lung cancer. Cancer Lett. 2012.","DOI":"10.69645\/GQCB7308"},{"key":"7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JTO.0b013e3181c5e366","article-title":"Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials","volume":"5","author":"Krug","year":"2010","journal-title":"J Thorac Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CMAR.S9661","article-title":"Interpreting clinical assays for histone deacetylase inhibitors","volume":"3","author":"Bertrand","year":"2011","journal-title":"Cancer Manag Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Johnstone","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2009","journal-title":"Cancer Lett"},{"key":"11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: What are the cancer relevant targets?","volume":"277","author":"Oehme","year":"2009","journal-title":"Cancer Lett"},{"key":"12","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Seto","year":"2007","journal-title":"Oncogene"},{"key":"13","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Chabner","year":"2009","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Lichenstein","year":"2008","journal-title":"Biochem J"},{"key":"15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Vu","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Bates","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.exphem.2012.06.008","article-title":"Impact of HDAC inhibitors on dendritic cell functions","volume":"40","author":"Mohty","year":"2012","journal-title":"Exp Hematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2174\/156800911797264761","article-title":"Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds","volume":"11","author":"Gregoire","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"19","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1021\/jm9002439","article-title":"Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression","volume":"52","author":"Bertrand","year":"2009","journal-title":"J Med Chem"},{"key":"20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","article-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","volume":"105","author":"Nakano","year":"2011","journal-title":"Respir Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1172\/JCI65385","article-title":"Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer","volume":"123","author":"Christofori","year":"2013","journal-title":"J Clin Invest"},{"key":"22","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","article-title":"Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma","volume":"15","author":"Willems","year":"2009","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2010.03.021","article-title":"Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy","volume":"46","author":"Willems","year":"2010","journal-title":"Eur J Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ijc.20395","article-title":"Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients","volume":"112","author":"Takahashi","year":"2004","journal-title":"Int J Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.lungcan.2004.03.021","article-title":"Histone deacetylase 1 mRNA expression in lung cancer","volume":"46","author":"Fujii","year":"2004","journal-title":"Lung Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"19629","DOI":"10.1073\/pnas.1117544108","article-title":"Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors","volume":"108","author":"Marks","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/0008-5472.CAN-10-2799","article-title":"Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors","volume":"71","author":"Lev","year":"2011","journal-title":"Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1158\/1541-7786.MCR-09-0187","article-title":"UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid","volume":"7","author":"Bernards","year":"2009","journal-title":"Mol Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.21297","article-title":"Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells","volume":"118","author":"Iwamoto","year":"2006","journal-title":"Int J Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1091\/mbc.11.6.2069","article-title":"Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells","volume":"11","author":"Gabrielli","year":"2000","journal-title":"Mol Biol Cell"},{"key":"31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/35055010","article-title":"Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases","volume":"3","author":"Almouzni","year":"2001","journal-title":"Nat Cell Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4161\/cc.4.5.1690","article-title":"Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin","volume":"4","author":"Sackett","year":"2005","journal-title":"Cell Cycle"},{"key":"33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.onc.1210779","article-title":"Histone deacetylase inhibitors induce mitotic slippage","volume":"27","author":"Gabrielli","year":"2008","journal-title":"Oncogene"},{"key":"34","doi-asserted-by":"crossref","first-page":"10429","DOI":"10.1073\/pnas.1734137100","article-title":"WNT7a induces E-cadherin in lung cancer cells","volume":"100","author":"Franklin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.05.032","article-title":"Semaphorins and their receptors in lung cancer","volume":"273","author":"Drabkin","year":"2009","journal-title":"Cancer Lett"},{"issue":"Suppl 1","key":"36","first-page":"S3","article-title":"Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect","volume":"28","author":"Prince","year":"2010","journal-title":"Invest New Drugs"},{"key":"37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0006-291X(02)02787-0","article-title":"Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity","volume":"300","author":"Kim","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 3","key":"38","first-page":"S272","article-title":"Small cell lung cancer: new clinical recommendations and current status of biomarker assessment","volume":"47","author":"Le Pechoux","year":"2011","journal-title":"Eur J Cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"e52753","DOI":"10.1371\/journal.pone.0052753","article-title":"Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression","volume":"7","author":"Broaddus","year":"2012","journal-title":"PLoS One"},{"key":"42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gregoire","year":"2011","journal-title":"Am J Pathol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:25:02Z","timestamp":1748625902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,3]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,6,30]]}},"alternative-id":["2056","24980825"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2056","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,3]]}}}